Ro 16-6491: a new reversible and highly selective MAO-B inhibitor protects mice from the dopaminergic neurotoxicity of MPTP.
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D000818:Animals; D001549:Benzamides / Q000627:therapeutic use*; D001921:Brain / Q000187:drug effects; D003342:Corpus Striatum / Q000187:drug effects; D004298:Dopamine / Q000378:metabolism; D008297:Male; D051379:Mice; D008995:Monoamine Oxidase / Q000378:metabolism; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use*; D018377:Neurotransmitter Agents / Q000378:metabolism; D010302:Parkinson Disease, Secondary / Q000139:chemically induced / Q000188:drug therapy*; D011725:Pyridines / Q000633:toxicity*; D051381:Rats; D012642:Selegiline / Q000627:therapeutic use; D013378:Substantia Nigra / Q000187:drug effects; D014439:Tyramine / Q000494:pharmacology
D001549:Benzamides; D008996:Monoamine Oxidase Inhibitors; D018377:Neurotransmitter Agents; D011725:Pyridines; D012642:Selegiline; C051040:Ro 16-6491; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D008995:Monoamine Oxidase; D004298:Dopamine; D014439:Tyramine